Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus

Author(s): Ritu Saini, William D. Tutrone, Jeffrey M. Weinberg

Journal Name: Current Pharmaceutical Design

Volume 11 , Issue 2 , 2005

Become EABM
Become Reviewer


Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population. Over the last several years, one of the major focuses in psoriasis research has been the development of biologic therapies for this disease. The aim of these therapies is to provide selective, immunologically directed intervention with fewer side effects than traditional therapies. The goal of this article is to review the progress of the biologic agents which are available, or under investigation for clinical use: infliximab, etanercept, efalizumab, alefacept, and adalimumab. In addition, two other investigational therapies, oral tazarotene and oral pimecrolimus will be discussed. Clinical data for these agents, including the most recent phase II and / or III study results, will be discussed, as well as the most recent safety data

Keywords: psoriasis, biologic therapy, t cell, cytokine, infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [273 - 280]
Pages: 8
DOI: 10.2174/1381612053382232
Price: $65

Article Metrics

PDF: 3